Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma
Katia Corano Scheri, … , John Varga, Tomoko Hayashida
Katia Corano Scheri, … , John Varga, Tomoko Hayashida
Published September 22, 2022
Citation Information: JCI Insight. 2022;7(21):e160977. https://doi.org/10.1172/jci.insight.160977.
View: Text | PDF
Research Article Cell biology

SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma

  • Text
  • PDF
Abstract

We previously reported that Smad anchor for receptor activation (SARA) plays a critical role in maintaining epithelial cell phenotype. Here, we show that SARA suppressed myofibroblast precursor transdifferentiation in a mouse model of scleroderma. Mice overexpressing SARA specifically in PDGFR-β+ pericytes and pan-leukocytes (SARATg) developed significantly less skin fibrosis in response to bleomycin injection compared with wild-type littermates (SARAWT). Single-cell RNA-Seq analysis of skin PDGFR-β+ cells implicated pericyte subsets assuming myofibroblast characteristics under fibrotic stimuli, and SARA overexpression blocked the transition. In addition, a cluster that expresses molecules associated with Th2 cells and macrophage activation was enriched in SARAWT mice, but not in SARATg mice, after bleomycin treatment. Th2-specific Il-31 expression was increased in skin of the bleomycin-treated SARAWT mice and patients with scleroderma (or systemic sclerosis, SSc). Receptor-ligand analyses indicated that lymphocytes mediated pericyte transdifferentiation in SARAWT mice, while with SARA overexpression the myofibroblast activity of pericytes was suppressed. Together, these data suggest a potentially novel crosstalk between myofibroblast precursors and immune cells in the pathogenesis of SSc, in which SARA plays a critical role.

Authors

Katia Corano Scheri, Xiaoyan Liang, Vidhi Dalal, I. Caroline Le Poole, John Varga, Tomoko Hayashida

×

Figure 2

Effects of SARA on pericyte transdifferentiation.

Options: View larger image (or click on image) Download as PowerPoint
Effects of SARA on pericyte transdifferentiation.
Representative images ...
Representative images of immunofluorescence staining on skin sections for pericyte marker NG2 (purple) and myofibroblast marker α-SMA (red) are shown (A). Pericytes are also expressing GFP in our animal model. Single channels and merged images are shown in the panel. Scale bar = 20 μm. Higher magnification for merged images is shown (B). The arrowheads in the merged image indicate the NG2+α-SMA+ cells in WT bleomycin-treated samples. Scale bar = 10 μm. Representative images from 3 independent experiments are shown. Negative control images are shown in Supplemental Figure 2B. The corrected total cell fluorescence (CTCF) quantification for α-SMA signal and the percentage of double-positive area for NG2+ and α-SMA+ in dermal layer are shown in the graphs (C). One-way ANOVA followed by Tukey’s multiple comparisons test: *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts